Product Overview: Voveran SR
Voveran SR 100 mg Novartis is a sustained-release formulation containing diclofenac sodium, a non-steroidal anti-inflammatory drug (NSAID) developed for controlled laboratory research applications. This pharmaceutical-grade compound enables researchers to investigate cyclooxygenase inhibition mechanisms, inflammatory pathway modulation, and analgesic properties in controlled experimental environments. The sustained-release matrix technology provides extended compound availability, making it valuable for pharmacokinetic and pharmacodynamic studies requiring prolonged drug exposure profiles. Research teams at Stroid UK Shop utilise this compound to examine prostaglandin synthesis inhibition, inflammation cascade interruption, and pain pathway modulation mechanisms in various experimental models.
Laboratory Applications
Researchers examine Voveran SR 100 mg for its dual COX-1 and COX-2 enzyme inhibition properties, studying how selective cyclooxygenase pathway blockade affects inflammatory mediator production. The sustained-release formulation allows investigation of prolonged anti-inflammatory effects, tissue penetration kinetics, and bioavailability parameters across different experimental timeframes. Scientists analyse this compound’s interaction with arachidonic acid metabolism, evaluating how diclofenac sodium modulates prostaglandin E2, thromboxane A2, and prostacyclin synthesis in cellular models. Studies within our diclofenac sodium category frequently compare this sustained-release preparation against immediate-release formulations to understand matrix-controlled drug delivery mechanisms.
Product Specifications
| Active Compound | Diclofenac Sodium |
|---|---|
| Concentration | 100 mg per tablet |
| Formulation | Sustained-Release Tablet |
| Manufacturer | Novartis |
| CAS Number | 15307-79-6 |
| Molecular Formula | C₁₄H₁₀Cl₂NNaO₂ |
| Storage | Room temperature, dry conditions |
This pharmaceutical preparation demonstrates consistent quality standards expected from Novartis manufacturing protocols, enabling reliable research outcomes across multiple experimental applications. The tablet matrix technology ensures controlled compound release kinetics, supporting studies requiring sustained therapeutic levels over extended observation periods. Researchers studying compounds available in our SARMs collection and peptides range often compare anti-inflammatory mechanisms with traditional NSAID pathways to understand tissue-selective modulation differences.
Research Compliance
This product is supplied strictly for in-vitro research and laboratory analysis purposes only. Voveran SR 100 mg Novartis is not intended for human consumption, therapeutic use, or any application outside controlled scientific research environments. Researchers must ensure proper handling protocols, appropriate disposal methods, and compliance with institutional research guidelines when conducting studies with this compound.
